Abstract
Erectile dysfunction (ED) has been revolutionized during the last two decades, as several treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first choice treatment option for ED by most physicians and patients due to their high efficacy rates and favourable safety profiles. Despite the fact that more than 50 million ED patients have been treated successfully worldwide with PDE5i several issues remain to be addressed. Patients with severe neurologic damage, diabetes mellitus, or severe vascular disease may be resistant to PDE5i. Inappropriate instructions, lack of follow-up and lack of patient-centered care models have been identified as main reasons for “nonresponse”, leading to drop-out rates of even > 50%. Preservation of corporal smooth muscle with chronic administration of PDE5i has been reported and there is a substantial body of evidence for beneficial effects of these drugs on endothelium and cardiovascular function. Finally, improvement of lower urinary symptoms after PDE5i administration has been reported and a possible role on treatment of premature ejaculation has been proposed. Many new PDE5i are candidates to enter the market in the forthcoming years. However, pharmacokinetic differences should be obvious to consider a truly better option for patients. Patients must be aware of all treatment options since no ideal treatment exists and physicians must offer personalized medicine to their patients in the future. The development and adaptation of a patient-centered care model in sexual medicine will increase efficacy and safety of current and future treatments.
Keywords: Erectile dysfunction, treatment, phosphodiesterase inhibitors
Current Pharmaceutical Design
Title: Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Volume: 15 Issue: 30
Author(s): K. Hatzimouratidis and D. G. Hatzichristou
Affiliation:
Keywords: Erectile dysfunction, treatment, phosphodiesterase inhibitors
Abstract: Erectile dysfunction (ED) has been revolutionized during the last two decades, as several treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first choice treatment option for ED by most physicians and patients due to their high efficacy rates and favourable safety profiles. Despite the fact that more than 50 million ED patients have been treated successfully worldwide with PDE5i several issues remain to be addressed. Patients with severe neurologic damage, diabetes mellitus, or severe vascular disease may be resistant to PDE5i. Inappropriate instructions, lack of follow-up and lack of patient-centered care models have been identified as main reasons for “nonresponse”, leading to drop-out rates of even > 50%. Preservation of corporal smooth muscle with chronic administration of PDE5i has been reported and there is a substantial body of evidence for beneficial effects of these drugs on endothelium and cardiovascular function. Finally, improvement of lower urinary symptoms after PDE5i administration has been reported and a possible role on treatment of premature ejaculation has been proposed. Many new PDE5i are candidates to enter the market in the forthcoming years. However, pharmacokinetic differences should be obvious to consider a truly better option for patients. Patients must be aware of all treatment options since no ideal treatment exists and physicians must offer personalized medicine to their patients in the future. The development and adaptation of a patient-centered care model in sexual medicine will increase efficacy and safety of current and future treatments.
Export Options
About this article
Cite this article as:
Hatzimouratidis K. and Hatzichristou G. D., Phosphodiesterase Type 5 Inhibitors: Unmet Needs, Current Pharmaceutical Design 2009; 15 (30) . https://dx.doi.org/10.2174/138161209789207042
DOI https://dx.doi.org/10.2174/138161209789207042 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Withdrawal Notice: Characterization of Glyoxal Modified LDL: Role in the Generation of Circulating Autoantibodies in Type 2 Diabetes Mellitus and Coronary Artery Disease
Current Drug Targets The Pathophysiology of CTGs and Types of Intrapartum Hypoxia
Current Women`s Health Reviews Integrated Nutritional Supports for Diabetic Patients During COVID-19 Infection: A Comprehensive Review
Current Diabetes Reviews Alkyl Chloroformates in Sample Derivatization Strategies for GC Analysis. Review on a Decade Use of the Reagents as Esterifying Agents
Current Pharmaceutical Analysis Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome
Current Vascular Pharmacology Protection by Natural Honey Against Hyperhomocysteinemia in Rats
Vascular Disease Prevention (Discontinued) Empowering Translational Research in Fetal Growth Restriction: Sheep and Swine Animal Models
Current Pharmaceutical Biotechnology Ambiguities in Neutrophil Extracellular Traps. Ongoing Concepts and Potential Biomarkers for Rheumatoid Arthritis: A Narrative Review
Current Rheumatology Reviews Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews The Effect of Statins on Postprandial Lipemia
Current Drug Targets Blood Pressure and Cognitive Impairment in the Elderly
Current Hypertension Reviews The Antidiabetic Therapeutic Potential of Dietary Polyphenols
Current Pharmaceutical Biotechnology Naringenin and Atherosclerosis: A Review of Literature
Current Pharmaceutical Biotechnology New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy Coarse Classification to Region-Scalable Refining for White Matter Lesions Segmentation in Multi-Channel MRI
CNS & Neurological Disorders - Drug Targets Prevention of Serum Albumin Glycation/Fibrillation by β-Cyclodextrin Functionalized Magnetic Nanoparticles
Protein & Peptide Letters Heart Failure in North America
Current Cardiology Reviews Polypharmacy in Cardiovascular Medicine: Problems and Promises!
Cardiovascular & Hematological Agents in Medicinal Chemistry Some Peculiar Effects of NO-Synthase Inhibition on the Structure and Function of Cardiovascular System
Current Pharmaceutical Biotechnology Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways
Current Neuropharmacology